{"id":"W4379259102","doi":"10.1158/2159-8290.cd-23-0153","title":"The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Center for Advancing Translational Sciences; Springworks Therapeutics; National Cancer Institute; Regeneron Pharmaceuticals","keywords":"Neutropenia; Vomiting; Nausea; Antagonist; Adverse effect; Medicine; Internal medicine; Liposarcoma; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Pharmacology; Oncology; Chemotherapy; Sarcoma; Pathology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001079606,0.0008242175,0.00150648,0.0002642825,0.0002861731,0.0005416535,0.0003899704,0.0004289453,0.001398019],"category_scores_gemma":[0.0005949305,0.0003146359,0.000637061,0.000325937,0.0003334631,0.0004100003,0.0001962962,0.001770962,0.0005079139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005679365,"about_ca_system_score_gemma":0.0006866571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009093791,"about_ca_topic_score_gemma":0.002784427,"domain_scores_codex":[0.9997147,0.0001278243,0.00001898166,0.00003802196,0.00004361236,0.00005687983],"domain_scores_gemma":[0.999616,0.00006354842,0.00007879834,0.00002769751,0.00003281613,0.0001811305],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2280081,0.05727201,0.02647074,0.001344147,0.001708055,0.0007408158,0.0007540196,0.006725449,0.3332889,0.0002480259,0.01012892,0.3333109],"study_design_scores_gemma":[0.1740961,0.6549256,0.1273839,0.000110557,0.001268676,0.001251091,0.0001854156,0.004288639,0.02204221,0.0002907774,0.01408251,0.00007446864],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923975,0.003934938,0.0004373975,0.0003488177,0.0000410981,0.0005360359,0.0007574139,0.00008531396,0.001461505],"genre_scores_gemma":[0.9917302,0.003145713,0.001125097,0.0004908424,0.00009007682,0.0004130892,0.001774919,0.00002922496,0.001200867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00150648,"threshold_uncertainty_score":0.005709589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02060908733489273,"score_gpt":0.3379968942313015,"score_spread":0.3173878068964088,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}